Condition: Hidradenitis Suppurativa · Sponsor: AbbVie
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for ulcerative colitis, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of HS. This study is "double-blinded", meaning that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo. This study is comprised of 3 periods. In Period 1, participants are randomized into 2 groups called treatment arms where each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In Period 2, participants are placed into 6 different groups depending on their placement and results in Period 1. Period 3 is the long-term extension period where participants will continue treatment from Period 2. Approximately 1328 adult and adolescent participants diagnosed with HS will be enrolled in approximately 300 sites worldwide. Participants will receive oral tablets of upadacitinib or placebo once daily for 36 weeks in…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Cahaba Dermatology & Skin Health Center /ID# 254876 | Birmingham, Alabama, United States | Active Not Recruiting |
| Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272564 | Fountain Hills, Arizona, United States | Completed |
| Medical Dermatology Specialists /ID# 254226 | Phoenix, Arizona, United States | Active Not Recruiting |
| Mayo Clinic - Scottsdale /ID# 254388 | Scottsdale, Arizona, United States | Active Not Recruiting |
| Banner University Medicine Dermatology /ID# 255853 | Tucson, Arizona, United States | Active Not Recruiting |
| Clinical Trials Institute - Northwest Arkansas /ID# 254924 | Fayetteville, Arkansas, United States | Active Not Recruiting |
| Burke Pharmaceutical Research /ID# 254238 | Hot Springs, Arkansas, United States | Completed |
| Arkansas Research Trials /ID# 254233 | North Little Rock, Arkansas, United States | Active Not Recruiting |
| NW Arkansas Clinical Trials Center /ID# 254311 | Rogers, Arkansas, United States | Completed |
| Private Practice - Dr. Tooraj Raoof /ID# 254374 | Encino, California, United States | Active Not Recruiting |
| Marvel Clinical Research /ID# 276228 | Huntington Beach, California, United States | Completed |
| Dermatology Research Associates /ID# 254846 | Los Angeles, California, United States | Active Not Recruiting |
+ 273 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05889182